Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection
- 18 August 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 3 (5) , 1020-1022
Abstract
Dipeptidyl peptidase-4 (DPP-4) is expressed ubiquitously in many tissues, including kidney, respiratory tract, and immune cells. Human DPP-4 has been identified as a functional receptor for the spike glycoprotein of the Middle East respiratory syndrome coronavirus. A large interface has been predicted in the docking of DPP-4/SARS-CoV-2 spike protein. Globally, 40% of diabetic patients develop diabetic kidney disease (DKD), a leading cause of end-stage renal disease. DPP-4 inhibitors possess anti-inflammatory properties which suggest their potential implication in DKD and SARS-CoV-2 immunopathogenesis.Keywords
This publication has 15 references indexed in Scilit:
- COVID-19: immunopathology and its implications for therapyNature Reviews Immunology, 2020
- Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targetsDiabetes, Obesity and Metabolism, 2020
- COVID-19 and diabetes: Knowledge in progressDiabetes Research and Clinical Practice, 2020
- COVID-19 and diabetes: Can DPP4 inhibition play a role?Diabetes Research and Clinical Practice, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26Emerging Microbes & Infections, 2020
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetesNature Reviews Nephrology, 2017
- Innate immunity in diabetes and diabetic nephropathyNature Reviews Nephrology, 2015
- Middle East respiratory syndromeThe Lancet, 2015
- DPP4 Inhibitors: a new approach in diabetes treatmentAdvances in Therapy, 2008